FDA to review peptide injections amid safety concerns and industry ties

U.S. health officials will review the safety and effectiveness of popular peptide injections in July. The decision comes amid growing concerns over their use and regulation. Many sellers currently bypass rules by labelling products as 'for research use only'. The FDA has highlighted risks linked to peptides such as BPC-157 and TB-500. These substances are banned by international sports authorities as doping agents. The agency’s new advisory panel includes over six members with ties to clinics, pharmacies, or online businesses selling peptides.

Among them is Dr. Haleem Mohammed, who operates clinics offering peptide injections alongside vitamins, testosterone, and weight loss treatments. Dr. Gabriel Alizaidy also promotes peptides to his social media followers and charges $500 for advice on sourcing them.

Bobby Harshbarger, a Tennessee state senator and pharmacist, works at Premiere Pharmacy, which sells compounded peptides. His support for former President Donald Trump’s 'Make America Great Again' agenda has drawn attention to his role in the industry. The FDA’s upcoming review will examine the risks and benefits of these widely used injections. The panel’s composition, featuring industry insiders, has sparked discussion about potential conflicts of interest. The outcome could impact how peptides are regulated and sold in the U.S.